Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Clinical Pharmacology Of Cancer Therapies In Older Adults

A. Hurria, S. Lichtman
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
This abbreviated review outlines the physiologic changes associated with aging, and examines how these changes may affect the pharmacokinetics and pharmacodynamics of anticancer therapies. We also provide an overview of studies that have been conducted evaluating the pharmacology of anticancer therapies in older adults, and issue a call for further research.
This paper references
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
A. Miller (1997)
10.1016/S0093-7754(03)00400-7
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.
J. Doroshow (2003)
Neurotoxicity of Taxol.
E. Rowinsky (1993)
10.1093/JNCI/DJM086
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
F. Scappaticci (2007)
10.1200/JCO.1992.10.7.1171
Influence of sex and age on fluorouracil clearance.
G. Milano (1992)
10.1111/J.1365-2125.2004.02228.X
Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).
R. Shah (2004)
10.1158/1078-0432.CCR-06-0200
Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients
A. Hurria (2006)
10.1007/s00280-002-0554-z
The effect of age on the early disposition of doxorubicin
J. Li (2003)
Physiologic Aspects of Aging: Impact on Cancer Management and Decision Making, Part I
R. Sawhney (2005)
10.1200/JCO.1984.2.12.1404
Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance.
R. Gelman (1984)
10.1097/00006254-200004000-00021
Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks.
S. Shaywitz (1999)
10.1200/JCO.2005.03.9289
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
S. Lichtman (2006)
10.1200/JCO.2006.07.5754
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
D. Jackman (2007)
10.1093/ANNONC/MDH079
Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients.
G. Marx (2004)
Phase II clinical trial of chemotherapy-naive patients 4 or 1⁄4 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
DM Jackman (2007)
Population pharmacokinetics and pharmacodynamics of oral etoposide Aging and pharmacology
G Toffoli (1997)
10.3109/07357900009012191
A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer
E. Dees (2000)
10.1016/J.EJCA.2006.11.004
International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency.
S. Lichtman (2007)
10.1200/JCO.2004.00.6148
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies.
D. Nyman (2005)
Clinical pharmacology of cancer therapies A Hurria and SM Lichtman
10.1200/JCO.2005.09.129
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer.
R. Camidge (2005)
10.1200/JCO.1997.15.2.833
High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency.
G. A. Smith (1997)
10.1136/ard.57.2.110
Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients
F. Bressolle (1998)
10.1023/A:1010687017717
Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel
R. Bruno (2004)
10.1007/s002800050897
Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma
P. Aita (1999)
10.1046/J.0306-5251.2001.01468.X
Population pharmacokinetics and pharmacodynamics of oral etoposide.
G. Toffoli (2001)
10.1200/JCO.2005.03.082
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.
A. T. Ten Tije (2005)
10.1002/(SICI)1097-0142(19971001)80:7<1302::AID-CNCR16>3.0.CO;2-B
Aging and pharmacology
R. Vestal (1997)
10.7326/0003-4819-130-6-199903160-00002
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
A. Levey (1999)
Pharmacology of oxaliplatin in solid
JH Doroshow (2003)
10.1200/JCO.2004.10.163
Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
H. Minami (2004)
10.1016/S0959-8049(96)00426-1
Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer.
R. Sorio (1997)
A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.
P. Fidias (2001)
10.1200/JCO.2004.02.175
Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.
L. Talarico (2004)
10.1007/s00280-001-0408-0
Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients
C. Poole (2002)
10.1016/S0749-0690(18)30188-5
Pharmacology of cancer chemotherapy in the older person.
S. Baker (1997)
10.1200/JCO.1999.17.1.409
Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.
R. Go (1999)
10.1200/JCO.1999.17.8.2412
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
R. Popescu (1999)
10.1046/J.1365-2125.2003.01956.X
Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.
K. Slaviero (2004)
10.1002/cncr.11407
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
10.1200/JCO.2003.11.015
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
C. Takimoto (2003)
Clinical pharmacokinetics of oxaliplatin: a critical review.
M. Graham (2000)
10.1111/j.1532-5415.1985.tb07117.x
Longitudinal Studies on the Rate of Decline in Renal Function with Age
R. Lindeman (1985)
10.1016/S0749-0690(18)30615-3
Altered pharmacokinetics in the elderly.
G. Yuen (1990)
10.1200/JCO.1992.10.6.948
Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia.
E. Rubin (1992)
10.1080/00365590310015750
Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance
I. Fehrman-Ekholm (2004)
Pharmacological analysis of etoposide in elderly patients with lung cancer.
M. Ando (1999)
10.1016/S0959-8049(02)00611-1
Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer.
C. Smorenburg (2003)
Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer.
A. Gauvin (2000)
British Journal of Cancer Cancer Research
(2008)
10.1159/000052832
Creatinine Clearance, Cockcroft-Gault Formula and Cystatin C: Estimators of True Glomerular Filtration Rate in the Elderly?
H. Burkhardt (2002)
10.1056/NEJMOA010957
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
D. Sargent (2001)
10.1016/S0009-9236(97)90166-1
Age and cytochrome P450‐linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions
E. Sotaniemi (1997)
Phase II clinical trial of chemotherapy-naive patients 4 or ¼ 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
D M Jackman (2007)
10.1200/JCO.2005.02.4091
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
E. Tan-chiu (2005)
10.1038/sj.bjc.6603049
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer
R. Sharma (2006)
10.1056/NEJM199912303412706
Underrepresentation of patients 65 years of age or older in cancer-treatment trials.
L. Hutchins (1999)
10.1023/A:1026403805756
Population Pharmacokinetics of Temozolomide in Cancer Patients
J. Jen (2004)
10.1093/QJMED/HCH051
Can creatinine clearance be accurately predicted by formulae in octogenarian in-patients?
E. Rimon (2004)
10.1093/JNCI/94.3.173
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.
C. Langer (2002)
10.1016/S0889-8588(05)70275-6
Aging and cancer in America. Demographic and epidemiologic perspectives.
R. Yancik (2000)



This paper is referenced by
10.1186/1479-5876-7-54
Institutional shared resources and translational cancer research.
P. Paoli (2009)
10.1007/978-0-387-89070-8_9
Chemotherapy for the Older Adult with Cancer
S. Mohile (2009)
10.2217/fon.13.120
Breast cancer in the elderly: reducing the losses.
C. Markopoulos (2013)
10.3390/scipharm85010008
Anticancer Dose Adjustment for Patients with Renal and Hepatic Dysfunction: From Scientific Evidence to Clinical Application
Tomi Hendrayana (2017)
10.1016/B978-1-4377-1398-5.10010-4
Chapter 10 – Novel and Targeted Therapies
M. Zauderer (2012)
10.6004/JNCCN.2009.0016
Geriatric assessment in older patients with breast cancer.
H. Klepin (2009)
10.6004/JNCCN.2013.0205
Management of elderly patients with cancer.
A. Hurria (2013)
10.18620/1866-8836-2015-4-1-2-8-13
Chemotherapy in the elderly - How intense should treatment be?
A. Zander (2015)
10.2217/WHE.12.18
Treatment of Metastatic Breast Cancer in Women Aged 65 Years and Older
T. Jolly (2012)
10.3892/ol.2019.10840
Prospective comparison of the value of CRASH and CARG toxicity scores in predicting chemotherapy toxicity in geriatric oncology
J. Zhang (2019)
10.1186/1471-2407-11-224
Clinical symptoms and chemotherapy completion in elderly patients with newly diagnosed acute leukemia: a retrospective comparison study with a younger cohort
Rong Hu (2010)
Treatment of acute lymphoblastic leukemia in older adults: now and the future.
M. Yilmaz (2017)
10.1016/B978-1-4377-1398-5.10009-8
Chapter 9 – Chemotherapy
S. Pal (2012)
10.1016/j.jgo.2017.11.003
Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer.
A. de Nonneville (2018)
How I Treat How I treat older patients with ALL
N. Goekbuget (2013)
10.4236/JCT.2013.47141
Treatment in Elderly Glioblastoma Patients: General Reduction of Standard Therapy Should Be Avoided. Prognostic Value of MGMT Is Questionable
J. Pichler (2013)
Online Database Featuring Author , Key Word and Full-Text Search Tolerability of Chemotherapy in Elderly Patients
Martin Hohenegger (2016)
10.2217/1745509X.4.2.113
Efficacy and safety of docetaxel in the elderly
S. Mohile (2008)
10.1007/s10147-011-0335-y
Comparison of safety and efficacy of S-1 monotherapy and S-1 plus cisplatin therapy in elderly patients with advanced gastric cancer
T. Tsushima (2011)
10.4236/AMI.2019.92003
Overview of Hematopoietic Stem Cells in Systemic Cancer Treatment, Aging, Pregnancy, and Radiation Hormesis
Aleksei N. Shoutko (2019)
10.1007/978-1-4471-4605-6_5
Pharmacology of Chemotherapy
C. Steer (2013)
10.1634/theoncologist.2014-0202
Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age.
A. Hurria (2015)
10.1159/000343608
Comprehensive geriatric assessment in oncology.
S. Mohile (2013)
10.1007/s10120-010-0566-z
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer
T. Tsushima (2010)
10.1007/s12029-019-00320-y
The Uptake and Efficacy of Neoadjuvant Therapy in Older Adults with Locally Advanced Esophogastric Cancer
P. Martin (2019)
10.4155/TDE.10.22
Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors.
H. Sarin (2010)
10.1007/s00393-012-0988-6
How I treat …
F. Moosig (2012)
10.1016/J.JGO.2012.01.003
Perioperative care of the elderly oncology patient: A report from the SIOG task force on the perioperative care of older patients with cancer
S. R. Kristjansson (2012)
10.1188/10.ONF.S1.17-26
Practical approaches to pharmacologic management of pain in older adults with cancer.
J. Brant (2010)
10.1016/j.jgo.2018.06.008
Clinical pharmacology of oncology agents in older adults: A comprehensive review of how chronologic and functional age can influence treatment-related effects.
Ginah Nightingale (2019)
10.1007/978-3-540-89891-7_37
Pharmacodynamic Evaluation: Oncology
François M. Lokiec (2011)
10.1053/j.seminoncol.2011.03.004
Geriatric oncology and palliative medicine.
Abdo S Haddad (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar